Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Antisense Therapy to Block the Kallikrein-kinin Pathway in COVID-19: A Phase II Randomized Controlled Trial

NCT04549922 is registered in ClinicalTrials.gov with Hospital do Coracao as lead sponsor.

NCT NCT04549922
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04549922 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Antisense Therapy to Block the Kallikrein-kinin Pathway in COVID-19: A Phase II Randomized Controlled Trial
Lead sponsor
Hospital do Coracao
Phase
Phase 2
Overall status
Completed
Start date
October 19, 2020
Completion date
December 9, 2021
Enrollment
111 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

covid19